The Pivot That Created a Tollbooth
XOMA (XOMA) is one of the tollbooth companies that appears in the context of Porter Stansberry’s Ignition Point pitch, though it is not a confirmed formal pick. Its story is a useful one because the company did not start out as a royalty aggregator. It reinvented itself, pivoting into what it now calls XOMA Royalty Corporation.
That pivot is the whole point. XOMA was historically a drug developer, and like many developers it learned how brutal the trial-by-trial grind can be. Instead of continuing to bet on its own candidates, it turned its remaining capital and expertise toward buying royalty and milestone interests in other companies’ programs.
From Developer to Aggregator
The transformation is more than a name change. As XOMA Royalty, the company now earns money in two ways. First, it collects royalties on licensed drug programs, a top-line share of sales when a partnered product reaches the market. Second, it holds milestone interests, which pay out when a drug hits development checkpoints such as a trial readout or a regulatory approval.
Neither of those requires XOMA to run a clinical trial, build a manufacturing plant, or market a drug. It simply owns a claim on other companies’ progress. That is the same capital-light structure Royalty Pharma popularized, applied at a much smaller scale.
How It Compares to the Big Aggregator
Royalty Pharma is the largest royalty aggregator in the world, and we profile its model in our Royalty Pharma piece. XOMA is the small-cap version of the same idea. The trade-off is straightforward: a smaller company can move more dramatically when a deal works out, but it also carries more concentration risk, because a handful of programs can represent an outsized share of its value.
That concentration cuts both ways. One milestone payment landing can be a meaningful event for a small-cap royalty holder, which is exactly what draws speculative investors to the model. But a single program that stalls can leave a noticeable hole.
The Lp(a) Connection
XOMA sits at the edge of the gene-silencing story rather than its center. It is not the company running an Lp(a) outcomes trial, and it is not the buyer of the olpasiran royalty, which Royalty Pharma acquired from Arrowhead for $250 million. XOMA’s role is quieter: it owns small royalty and milestone positions across a spread of licensed programs, some of which touch the same cardiovascular and rare-disease territory that animates the Ignition Point thesis.
That thesis is the barbell Porter lays out, pairing tollbooth ballast with speculative developers. The capital-light logic behind it is the same one he explains in his broader Royalty Riches teardown.
What to Watch
The honest caveat with XOMA is liquidity and visibility. Small royalty aggregators often hold positions in programs that are not yet generating meaningful revenue, which means the value is tied up in future milestones that are hard to price from the outside. Investors are betting on management’s ability to keep finding deals and on the underlying programs hitting their checkpoints.
For anyone trying to understand the tollbooth end of Porter’s barbell, XOMA is the reminder that the royalty model scales all the way down. The economics are the same; only the size of the bet changes.
The Milestone Business
Royalties are only half of XOMA’s model. The other half is milestones, payments that trigger when a partnered drug hits a development checkpoint. Those checkpoints are the binary events biotech investors know well: a positive trial readout, a regulatory filing, an approval, a first commercial sale. Each one unlocks a payment that XOMA does not have to earn through sales.
Milestones behave differently from royalties. A royalty is a slow drip tied to revenue; a milestone is a lump sum tied to progress. For a small company, a single milestone landing can be a material event, which is why XOMA’s stock can move on news about its partners’ programs even when XOMA itself has nothing to report.
That optionality is the small-cap appeal. A big aggregator like Royalty Pharma barely notices one milestone among hundreds of programs, but XOMA’s smaller book means each checkpoint carries more weight, in both directions. The concentration that can multiply the upside is the same concentration that can deepen the downside.
The result is a model that looks quiet between events and dramatic when they hit. Investors who buy XOMA are really buying a portfolio of future checkpoints, and the value of the stock is the market’s best guess at how many of them will actually pay out. For anyone watching the tollbooth end of the barbell, that is the difference between a steady royalty annuity and a milestone-driven wager.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.